



**You refuse to compromise.**  
We couldn't agree more.

**With so much at stake, there is no room for compromise.**  
Edwards SAPIEN 3 TAVI helps you:

Deliver the outcomes you demand

**1%** death or disabling  
stroke at 1 year<sup>1</sup>

---


Perfect the pathway with low procedural complications

**96%** of patients discharged to  
the comfort of their home<sup>1</sup>


---

Control for the future of patients with longer life expectancies

**100%** successful post-TAVI  
coronary access<sup>2</sup>



# The valve designed to meet your Higher Standard.



\*On the primary endpoint of death, stroke, and rehospitalization at 1 year

1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. *N Engl J Med.* 2019.
2. Tarantini G, Fovino LN, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. *Circ Cardiovasc Interv.* 2020;13(7):e008972.
3. Leon MB, Smith CR, Mack MJ, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. *N Engl J Med.* 2010.
4. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med.* 2016.
5. Nazif T, Daniels D, McCabe J, Chehab B, et al. Real-world experience with the SAPIEN 3 Ultra TAVI: A propensity matched analysis from the United States. Presented virtually at TVT Connect 2020.

For professional use. For a listing of indication, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult [eifu.edwards.com](http://eifu.edwards.com) where applicable).

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Material for distribution only in countries with applicable health authority product registrations. Material not intended for distribution in USA or Japan. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN XT, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, SAPIEN, SAPIEN XT, SAPIEN 3, and SAPIEN 3 Ultra are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

These materials are sponsored solely by Edwards and were not authorized by any other manufacturer.

© 2021 Edwards Lifesciences Corporation. All rights reserved. PP-EU-1436 v1.0

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • [edwards.com](http://edwards.com)

